Key Segments:
By Service
-
Contract Development
-
Process Development
-
Analytical Method Development & Testing
-
Formulation Development
-
IND-Enabling Preclinical Support
-
-
Contract Manufacturing
-
Drug Substance
-
Drug Product
-
By Molecule Type
-
Small Molecules
-
Large Molecules
-
Advanced Therapies
By Phase
-
Preclinical
-
Phase I
-
Phase II
By Therapeutic Area
-
Oncology
-
Neurology
-
Infectious Diseases
-
Rare Diseases
-
Others
By End Use
-
Emerging Biotechs
-
Pharmaceutical Companies
-
Academic & Research Institutions
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Lonza, Thermo Fisher Scientific, Catalent, Samsung Biologics, WuXi AppTec, Recipharm, Charles River Laboratories, and Piramal Pharma Solutions.
Key opportunities include integrated CRO and CDMO platforms, advanced therapy capacity, clinical aseptic fill-finish expansion, and rare disease programme support.
The market is driven by rising emerging biotech pipelines, outsourcing of IND-enabling development, and the high cost of in-house GMP capacity.
The Contract Manufacturing segment dominated the Investigational New Drug CDMO Market, accounting for approximately 54% market share.
The North America region dominated the Investigational New Drug CDMO Market in 2025 with approximately 46.0% share, driven by dense biotech funding and experienced early-phase CDMO capacity.
